Bayer Aktiengesellschaft (BAYRY) shares rose 6.56%, trading at $14.45, up $0.89, after its subsidiary Monsanto announced a proposed nationwide class settlement to resolve current and future Roundup related claims.
The agreement aims to address claims alleging non Hodgkin lymphoma injuries through a long term compensation program, with Monsanto committing to capped annual payments totaling up to $7.25 billion over 21 years, subject to court approval. The settlement is part of a broader strategy to contain ongoing litigation alongside a pending U.S. Supreme Court review.
The company said the combined legal approach is intended to reduce uncertainty and provide greater control over future litigation costs. However, Bayer expects to increase its litigation provisions and liabilities to €11.8 billion from €7.8 billion, reflecting the financial impact of the settlements.
Bayer also indicated that total litigation related payouts could reach approximately €5 billion in 2026, which is expected to result in negative free cash flow for the year. The company secured an $8 billion bank loan facility to support immediate financing needs.
On the day of the announcement, BAYRY traded between $13.77 and $14.66. Trading volume was 607,017 shares compared with an average of 871,490 shares. Bayer's 52 week range is $5.30 to $14.66.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.